Literature DB >> 23360377

Vector production in an academic environment: a tool to assess production costs.

Aaron Boeke1, Patrick Doumas, Lilith Reeves, Kyle McClurg, Daniela Bischof, Lina Sego, Alisha Auberry, Mohan Tatikonda, Kenneth Cornetta.   

Abstract

Generating gene and cell therapy products under good manufacturing practices is a complex process. When determining the cost of these products, researchers must consider the large number of supplies used for manufacturing and the personnel and facility costs to generate vector and maintain a cleanroom facility. To facilitate cost estimates, the Indiana University Vector Production Facility teamed with the Indiana University Kelley School of Business to develop a costing tool that, in turn, provides pricing. The tool is designed in Microsoft Excel and is customizable to meet the needs of other core facilities. It is available from the National Gene Vector Biorepository. The tool allows cost determinations using three different costing methods and was developed in an effort to meet the A21 circular requirements for U.S. core facilities performing work for federally funded projects. The costing tool analysis reveals that the cost of vector production does not have a linear relationship with batch size. For example, increasing the production from 9 to18 liters of a retroviral vector product increases total costs a modest 1.2-fold rather than doubling in total cost. The analysis discussed in this article will help core facilities and investigators plan a cost-effective strategy for gene and cell therapy production.

Entities:  

Mesh:

Year:  2013        PMID: 23360377      PMCID: PMC4015083          DOI: 10.1089/hgtb.2012.213

Source DB:  PubMed          Journal:  Hum Gene Ther Methods        ISSN: 1946-6536            Impact factor:   2.396


  10 in total

1.  Core facilities: maximizing the return on investment.

Authors:  Gregory K Farber; Linda Weiss
Journal:  Sci Transl Med       Date:  2011-08-10       Impact factor: 17.956

2.  Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.

Authors:  David L Porter; Bruce L Levine; Michael Kalos; Adam Bagg; Carl H June
Journal:  N Engl J Med       Date:  2011-08-10       Impact factor: 91.245

3.  Cancer regression in patients after transfer of genetically engineered lymphocytes.

Authors:  Richard A Morgan; Mark E Dudley; John R Wunderlich; Marybeth S Hughes; James C Yang; Richard M Sherry; Richard E Royal; Suzanne L Topalian; Udai S Kammula; Nicholas P Restifo; Zhili Zheng; Azam Nahvi; Christiaan R de Vries; Linda J Rogers-Freezer; Sharon A Mavroukakis; Steven A Rosenberg
Journal:  Science       Date:  2006-08-31       Impact factor: 47.728

Review 4.  Retroviral vector production in the National Gene Vector Laboratory at Indiana University.

Authors:  K Cornetta; L Matheson; C Ballas
Journal:  Gene Ther       Date:  2005-10       Impact factor: 5.250

5.  A framework for managing core facilities within the research enterprise.

Authors:  Rand Haley
Journal:  J Biomol Tech       Date:  2009-09

6.  Gene therapy for immunodeficiency due to adenosine deaminase deficiency.

Authors:  Alessandro Aiuti; Federica Cattaneo; Stefania Galimberti; Ulrike Benninghoff; Barbara Cassani; Luciano Callegaro; Samantha Scaramuzza; Grazia Andolfi; Massimiliano Mirolo; Immacolata Brigida; Antonella Tabucchi; Filippo Carlucci; Martha Eibl; Memet Aker; Shimon Slavin; Hamoud Al-Mousa; Abdulaziz Al Ghonaium; Alina Ferster; Andrea Duppenthaler; Luigi Notarangelo; Uwe Wintergerst; Rebecca H Buckley; Marco Bregni; Sarah Marktel; Maria Grazia Valsecchi; Paolo Rossi; Fabio Ciceri; Roberto Miniero; Claudio Bordignon; Maria-Grazia Roncarolo
Journal:  N Engl J Med       Date:  2009-01-29       Impact factor: 91.245

7.  Effect of gene therapy on visual function in Leber's congenital amaurosis.

Authors:  James W B Bainbridge; Alexander J Smith; Susie S Barker; Scott Robbie; Robert Henderson; Kamaljit Balaggan; Ananth Viswanathan; Graham E Holder; Andrew Stockman; Nick Tyler; Simon Petersen-Jones; Shomi S Bhattacharya; Adrian J Thrasher; Fred W Fitzke; Barrie J Carter; Gary S Rubin; Anthony T Moore; Robin R Ali
Journal:  N Engl J Med       Date:  2008-04-27       Impact factor: 91.245

8.  Safety and efficacy of gene transfer for Leber's congenital amaurosis.

Authors:  Albert M Maguire; Francesca Simonelli; Eric A Pierce; Edward N Pugh; Federico Mingozzi; Jeannette Bennicelli; Sandro Banfi; Kathleen A Marshall; Francesco Testa; Enrico M Surace; Settimio Rossi; Arkady Lyubarsky; Valder R Arruda; Barbara Konkle; Edwin Stone; Junwei Sun; Jonathan Jacobs; Lou Dell'Osso; Richard Hertle; Jian-xing Ma; T Michael Redmond; Xiaosong Zhu; Bernd Hauck; Olga Zelenaia; Kenneth S Shindler; Maureen G Maguire; J Fraser Wright; Nicholas J Volpe; Jennifer Wellman McDonnell; Alberto Auricchio; Katherine A High; Jean Bennett
Journal:  N Engl J Med       Date:  2008-04-27       Impact factor: 91.245

9.  Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy.

Authors:  Nathalie Cartier; Salima Hacein-Bey-Abina; Cynthia C Bartholomae; Gabor Veres; Manfred Schmidt; Ina Kutschera; Michel Vidaud; Ulrich Abel; Liliane Dal-Cortivo; Laure Caccavelli; Nizar Mahlaoui; Véronique Kiermer; Denice Mittelstaedt; Céline Bellesme; Najiba Lahlou; François Lefrère; Stéphane Blanche; Muriel Audit; Emmanuel Payen; Philippe Leboulch; Bruno l'Homme; Pierre Bougnères; Christof Von Kalle; Alain Fischer; Marina Cavazzana-Calvo; Patrick Aubourg
Journal:  Science       Date:  2009-11-06       Impact factor: 47.728

10.  Adenovirus-associated virus vector-mediated gene transfer in hemophilia B.

Authors:  Amit C Nathwani; Edward G D Tuddenham; Savita Rangarajan; Cecilia Rosales; Jenny McIntosh; David C Linch; Pratima Chowdary; Anne Riddell; Arnulfo Jaquilmac Pie; Chris Harrington; James O'Beirne; Keith Smith; John Pasi; Bertil Glader; Pradip Rustagi; Catherine Y C Ng; Mark A Kay; Junfang Zhou; Yunyu Spence; Christopher L Morton; James Allay; John Coleman; Susan Sleep; John M Cunningham; Deokumar Srivastava; Etiena Basner-Tschakarjan; Federico Mingozzi; Katherine A High; John T Gray; Ulrike M Reiss; Arthur W Nienhuis; Andrew M Davidoff
Journal:  N Engl J Med       Date:  2011-12-10       Impact factor: 176.079

  10 in total
  3 in total

Review 1.  Dr. Sonia Skarlatos and the National Heart, Lung, and Blood institute translational research and resource programs.

Authors:  Cheryl L McDonald
Journal:  Hum Gene Ther       Date:  2013-11       Impact factor: 5.695

2.  Partnership between CTSI and business schools can promote best practices for core facilities and resources.

Authors:  Lilith Reeves; Linda M Dunn-Jensen; Timothy T Baldwin; Mohan V Tatikonda; Kenneth Cornetta
Journal:  Clin Transl Sci       Date:  2013-04-19       Impact factor: 4.689

3.  The Access Technology Program of the Indiana Clinical Translational Sciences Institute (CTSI): A model to facilitate access to cutting-edge technologies across a state.

Authors:  Christie M Orschell; Todd C Skaar; Melanie E DeFord; Joel Ybe; Julie Driscol; Christine Drury; Lilith Reeves; Monte S Willis; Jill L Reiter; Jenna York; Rob Orr; Jeanette N McClintick; Thomas G Sors; Joe Hunt; Kenneth Cornetta; Anantha Shekhar
Journal:  J Clin Transl Sci       Date:  2020-08-19
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.